$0.17
+0.00 (+1.01%)
Open$0.17
Previous Close$0.17
Day High$0.18
Day Low$0.16
52W High$1.09
52W Low$0.10
Volume—
Avg Volume722.8K
Market Cap10.12M
P/E Ratio—
EPS$-2.06
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+14,731.9% upside
Current
$0.17
$0.17
Target
$25.14
$25.14
$18.28
$25.14 avg
$30.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 204.9K | 501.7K | 427.8K |
| Net Income | -245,012,378 | -539,806,952 | 33.9K |
| Profit Margin | -119,566.5% | -113,588.2% | 7.9% |
| EBITDA | -244,197,285 | -567,900,662 | 68.2K |
| Free Cash Flow | — | — | 23.2K |
| Rev Growth | -59.2% | -59.2% | +6.7% |
| Debt/Equity | 0.00 | 0.00 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |